Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2875 of 3499 entries
View as:

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00482625 Org: User:
Start: 06/30/07 End: 09/30/13 Due: 09/30/14

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00381550 Org: User:
Start: 08/31/06 End: 03/31/11 Due: 03/31/12

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00088894 Org: User:
Start: 06/30/04 End: - Due: -

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00082914 Org: User:
Start: 03/31/04 End: 07/31/06 Due: 07/31/07

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02631733 Org: User:
Start: 05/31/17 End: 05/24/23 Due: 05/24/24

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Phase: N/A Priority: Normal
NCT ID: NCT04439318 Org: User:
Start: 02/25/16 End: 12/31/25 Due: 12/31/26

Clinical and Genetic Studies of Li-Fraumeni Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01443468 Org: User:
Start: 01/17/12 End: - Due: -

Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00079352 Org: User:
Start: 04/30/04 End: - Due: -

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00387751 Org: User:
Start: 08/31/06 End: 01/31/10 Due: 01/31/11

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00002759 Org: User:
Start: 06/30/96 End: - Due: -

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00005950 Org: User:
Start: 04/30/00 End: - Due: -

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04460937 Org: User:
Start: 04/09/21 End: 12/18/25 Due: 12/18/26

Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00182702 Org: User:
Start: 07/31/05 End: - Due: -

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Phase: N/A Priority: Normal
NCT ID: NCT05797246 Org: User:
Start: 08/02/23 End: 11/02/26 Due: 11/02/27

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02487979 Org: User:
Start: 02/16/16 End: 12/31/21 Due: 12/31/22

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT02192541 Org: User:
Start: 12/02/14 End: 02/25/16 Due: 02/25/17

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT01711554 Org: User:
Start: 02/04/13 End: 03/17/26 Due: 03/17/27

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Phase: N/A Priority: Normal
NCT ID: NCT04574583 Org: User:
Start: 11/24/20 End: 05/19/23 Due: 05/19/24

AFP464 in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00369200 Org: User:
Start: 06/30/06 End: - Due: -

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00738881 Org: User:
Start: 10/31/08 End: 12/31/14 Due: 12/31/15

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02243579 Org: User:
Start: 10/15/14 End: 04/01/19 Due: 04/01/20

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

Phase: N/A Priority: Normal
NCT ID: NCT02365480 Org: User:
Start: 06/16/16 End: 12/13/19 Due: 12/13/20

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01281150 Org: User:
Start: 01/31/11 End: - Due: -

Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00516295 Org: User:
Start: 02/29/08 End: 01/31/10 Due: 01/31/11

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00509587 Org: User:
Start: 06/30/07 End: 08/31/13 Due: 08/31/14